Rights and permissions
About this article
Cite this article
Use of CV secondary prevention drugs leaves a lot to be desired. Pharmacoecon. Outcomes News 637, 5 (2011). https://doi.org/10.2165/00151234-201106370-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106370-00012